Arcutis Vertex: Which Pharmaceutical Stock Is Better in 2026
In 2026, investors face a classic showdown: a rapid-growth dermatology
Understanding when it's too late to start a retirement plan is crucial for your financial health. This article provides insights to help you assess your situation.
22,641 articlesIn 2026, investors face a classic showdown: a rapid-growth dermatology
A new research note sets a bold 2027 price target for Procter & Gamble, arguing efficiency gains and steady demand co...
Inflation is squeezing wallets, but Synchrony’s credit numbers improving narrative suggests the everyday consumer is ...
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
MicroStrategy unveils a refreshed liquidity framework, lifting cash reserves but leaving questions about its long-ter...
A new industry report shows on-time flight arrivals at their worst since 2014, pushed by higher fuel costs and volati...
Rising debt servicing is taking an ever-larger bite of federal receipts, with a key watchdog warning the trend could ...
In 2026, workers using AI are finishing tasks faster, but broad productivity data remains subdued. Economists compare...
A clear, investor-focused guide to the IMSR 2025 Earnings Transcript. Learn what the numbers mean for the company’s p...
Austin Niemiec returns to lead Rocket Pro as executives depart, signaling a strengthened wholesale channel amid a vol...
As the US Treasury aims to rebuild its cash balance toward 900B by June, Bitcoin traders face a potential liquidity s...
As Rocket Lab nears a pivotal earnings print, investors are quietly growing more bullish. This piece breaks down why ...